 |
|
New Study on Effects of Disclosing Financial Interests on Participation in Medical Research
October 06, 2008Baltimore, MD. - Knowing how an investigator is paid for running a research study surprisingly plays a small role in patients' willingness to take part in clinical trials. However, according to a new Johns Hopkins University study more participants are troubled when they are told that the investigator could profit or lose money depending on the results.
In an effort to learn more about the effects of disclosing an investigator's financial interests on potential study participants, researchers from the Johns Hopkins Berman Institute of Bioethics, Duke University Medical Center, and Wake Forest University surveyed 470 patients from an outpatient cardiology clinic. Each of these patients, who were diagnosed with coronary artery disease, agreed to go through a consent process over the phone for a hypothetical clinical trial.
The study, published in the October issue of the American Heart Journal, found that simply revealing an investigator's financial interest in a study does little to affect the patient's decisions to enroll in a hypothetical clinical trial. What the study did find was that patients were more concerned about certain types of financial interests, especially when the investigator owned stock in the company financing the study.
"Disclosure of investigators' financial interests in research does not substantially affect a person's willingness to participate," says Jeremy Sugarman, M.D., senior author of the study and Harvey M. Meyerhoff Professor of Bioethics and Medicine at the Johns Hopkins Berman Institute of Bioethics, however, "ethically it's important that the patient's 'right to know' is respected before they consent to enroll in research."
"What seems to be important in the decision-making process was the patients' pre-existing level of trust in medical research in general," says Dr. Kevin Weinfurt, a medical psychologist at Duke and the lead author of the study.
The team of researchers first assessed the patients' overall level of trust in medical research. Investigators then randomly assigned them to one of three disclosure groups: Members of one group were told the clinic involved in the study would receive per capita payments per enrollee that would be used to cover the costs of the trial, including the doctor's salary. Participants in a second group were told that the investigator held stock in the company sponsoring the research. There were no disclosure statements made to members of the third group.
When asked how likely they would be to join a clinical trial, members of all three groups expressed a moderate degree of willingness to do so. Still, there were some important differences between the groups.
Patients who heard about stock ownership were less willing than those in the other two groups to indicate that they would participate in the study. In addition, they spontaneously offered three times the number of negative comments about the relationship than participants in the other groups, using words like, "disingenuous," "unacceptable," and "unethical." In addition, ten members of the group that were told about stock ownership in the company sponsoring the trial, spontaneously said they would not take part in the trial compared with only one such comment from the other two groups.
In general, members of the per capita group felt that a financial arrangement that helped cover costs of the trial was acceptable, saying, "OK, that sounds more appropriate. So there's no payment to him, but through the university. OK, I'm good."
But some members in the group that was told about stock ownership found positive things to say about that arrangement, too. One person volunteered that "It looks like he'd have this real incentive for this thing to go real well, and I guess that's all to the good."
"The findings of this study make it clear that policy makers need to continue to address the issue of conflicts of interest in research conducted by investigators who stand to profit from the results of clinical trials," says Sugarman. When it comes to financial disclosure between investigators and research participants Sugarman says, "Policy makers may want to consider more restrictive policies for equity relationships than for other financial interests in research."
It's important to note that participants in the study were disproportionately middle-to higher income white men, and the researchers say lower income participants from other racial groups might feel differently about financial relationships between researchers and sponsoring companies.
The study was funded by a grant from the National Heart, Lung, and Blood Institute.
Other researchers involved in the study include Joelle Friedman, Chantelle Hardy, Alice Fortune-Greely, Janice Lawlor, Jennifer Allsbrook, Li Lin and Kevin Schulman, of Duke, and Mark Hall, from Wake Forest University.
Johns Hopkins Berman Institute of Bioethics
"Disclosure of investigators' financial interests in research does not substantially affect a person's willingness to participate," says Jeremy Sugarman, M.D., senior author of the study and Harvey M. Meyerhoff Professor of Bioethics and Medicine at the Johns Hopkins Berman Institute of Bioethics, however, "ethically it's important that the patient's 'right to know' is respected before they consent to enroll in research."
"What seems to be important in the decision-making process was the patients' pre-existing level of trust in medical research in general," says Dr. Kevin Weinfurt, a medical psychologist at Duke and the lead author of the study.
The team of researchers first assessed the patients' overall level of trust in medical research. Investigators then randomly assigned them to one of three disclosure groups: Members of one group were told the clinic involved in the study would receive per capita payments per enrollee that would be used to cover the costs of the trial, including the doctor's salary. Participants in a second group were told that the investigator held stock in the company sponsoring the research. There were no disclosure statements made to members of the third group.
When asked how likely they would be to join a clinical trial, members of all three groups expressed a moderate degree of willingness to do so. Still, there were some important differences between the groups.
Patients who heard about stock ownership were less willing than those in the other two groups to indicate that they would participate in the study. In addition, they spontaneously offered three times the number of negative comments about the relationship than participants in the other groups, using words like, "disingenuous," "unacceptable," and "unethical." In addition, ten members of the group that were told about stock ownership in the company sponsoring the trial, spontaneously said they would not take part in the trial compared with only one such comment from the other two groups.
In general, members of the per capita group felt that a financial arrangement that helped cover costs of the trial was acceptable, saying, "OK, that sounds more appropriate. So there's no payment to him, but through the university. OK, I'm good."
But some members in the group that was told about stock ownership found positive things to say about that arrangement, too. One person volunteered that "It looks like he'd have this real incentive for this thing to go real well, and I guess that's all to the good."
"The findings of this study make it clear that policy makers need to continue to address the issue of conflicts of interest in research conducted by investigators who stand to profit from the results of clinical trials," says Sugarman. When it comes to financial disclosure between investigators and research participants Sugarman says, "Policy makers may want to consider more restrictive policies for equity relationships than for other financial interests in research."
It's important to note that participants in the study were disproportionately middle-to higher income white men, and the researchers say lower income participants from other racial groups might feel differently about financial relationships between researchers and sponsoring companies.
The study was funded by a grant from the National Heart, Lung, and Blood Institute.
Other researchers involved in the study include Joelle Friedman, Chantelle Hardy, Alice Fortune-Greely, Janice Lawlor, Jennifer Allsbrook, Li Lin and Kevin Schulman, of Duke, and Mark Hall, from Wake Forest University.
Johns Hopkins Berman Institute of Bioethics
Medical Research Current Events and Medical Research News RSSPlant polymerases IV and V are special forms of Polymerase II
It's a little like finding out that Superman is actually Clark Kent. A team of biologists at Washington University in St. Louis has discovered that two vital cellular components, nuclear RNA Polymerases IV and V (Pol IV and V), found only in plants, are actually specialized forms of RNA Polymerase II, an essential enzyme of all eukaryotic organisms, including humans.
Team finds breast cancer gene linked to disease spread
A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death.
Mayo researchers offer new insight into effectiveness of procedure to stop heavy menstrual bleeding
Experts estimate that 20 percent of women experience excessive or prolonged menstrual bleeding at some time during their lives, particularly as they approach menopause.
Scientists Identify New Congenital Neutropenia Syndrome and Causative Gene Mutation
A team of scientists has discovered a new syndrome associated with severe congenital neutropenia (SCN), a rare disorder in which children lack sufficient infection-fighting white cells, and identified the genetic cause of the syndrome: mutations in the gene Glucose-6-phosphatase, catalytic subunit 3 (G6PC3).
Simple Model Predicts Those at Risk for Chronic Kidney Disease
Traditionally, doctors have had no clear way to predict which of their patients might be headed down the road to chronic kidney disease (CKD).
Case Western Reserve professor helps control infectious diseases with models and math
Can an algebraic equation hold the secret to eradicating malaria or schistosomiasis? A Case Western Reserve University mathematics professor is utilizing the combination of algorithms and models in an effort to assist his medical colleagues in the fight against infectious diseases.
Groundbreaking, inexpensive, pocket-sized ultrasound device can help treat cancer, relieve arthritis
A prototype of a therapeutic ultrasound device, developed by a Cornell graduate student, fits in the palm of a hand, is battery-powered and packs enough punch to stabilize a gunshot wound or deliver drugs to brain cancer patients.
Potential autoimmunity-inducing cells found in healthy adults
It's not just patients with autoimmune diseases like lupus and rheumatoid arthritis (RA) that have self-attacking immune cells-healthy people have them too, according to a new report in the Journal of Experimental Medicine.
Common Treatment for Chronic Prostatitis Fails to Reduce Symptoms
Alfuzosin, a drug commonly prescribed for men with chronic prostatitis, a painful disorder of the prostate and surrounding pelvic area, failed to significantly reduce symptoms in recently diagnosed men who had not been previously treated with this drug.
Treatment for men's pelvic pain found ineffective
A commonly prescribed drug for men suffering from a painful pelvic condition failed to significantly reduce patients' symptoms in an international study led by Queen's University professor and urologist at Kingston General Hospital, Curtis Nickel.
More Medical Research Current Events and Medical Research News Articles
 | Physician Assistant's Guide to Research And Medical Literature Physician Assistant's Guide to Research and Medical Literature is a step-by-step starting point for learning how to conduct and interpret research to meet all these needs. Dr. Blessing and his experienced contributing authors (all PA educators and clinicians) introduce readers to the principles and the pitfalls of health care research, punctuated with vignettes from the PA... |
 | Practical Statistics for Medical Research (Statistics texts) by Douglas G. Altman Practical Statistics for Medical Research is a problem-based text for medical researchers, medical students, and others in the medical arena who need to use statistics but have no specialized mathematics background. The author draws on twenty years of experience as a consulting medical statistician to provide clear explanations to key statistical concepts, with a firm emphasis on practical... |
 | International Handbook of Research in Medical Education (2 Vol. Set) (Springer International Handbooks of Education) The International Handbook of Research in Medical Education is a review of current research findings and contemporary issues in health sciences education. The orientation is towards research evidence as a basis for informing policy and practice in education. Although most of the research findings have accrued from the study of medical education, the Handbook will be useful to teachers and... |
 | Statistical Methods in Medical Research by Peter Armitage, Geoffrey Berry, J. N. S. Matthews Presents statistical techniques frequently used in medical research in an understandable format for the non-mathematician. Since the third edition, there have been many developments in statistical techniques. The fourth edition aims to provide the medical statistician with an accessible guide to these techniques and to reflect the extent of their usage in medical research. Uses examples... |
 | Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials (Critical Issues in Health and Medicine) (Critical Issues in Health and Medicine) by Jill A. Fisher Today, more than 75 percent of pharmaceutical drug trials in the United States are being conducted in the private sector. Once the sole province of academic researchers, these important studies are now being outsourced to non-academic physicians.According to Jill A. Fisher, this major change in the way medical research is performed is the outcome of two problems in U.S. health care: decreasing... |
 | What the Doctor Didn't Say: The Hidden Truth about Medical Research by Jerry Menikoff, Edward P. Richards Millions of people each year decide to participate in clinical trials--medical research studies involving an innovative treatment for a medical problem. For the patient, such participation can sometimes be a life-saving choice. But it can also be just the opposite. Our country years ago adopted rules designed to assure that people are making informed choices about participation. This book... |
| Medical Statistics from Scratch by David Bowers This long awaited second edition of this bestseller continues to provide a comprehensive, user friendly, down-to-earth guide to elementary statistics. The book presents a detailed account of the most important procedures for the analysis of data, from the calculation of simple proportions, to a variety of statistical tests, and the use of regression models for modeling of clinical outcomes. ... | |
 | Research Methodology in the Medical and Biological Sciences by Petter Laake, Haakon Breien Benestad Providing easy-to-access information, this unique sourcebook covers the wide range of topics that a researcher must be familiar with in order to become a successful experimental scientist. Perfect for aspiring as well as practicing professionals in the medical and biological sciences it discusses a broad range of topics that are common, yet not traditionally considered part of formal curricula.... |
| Turn the Web into a research associate.: An article from: Trial by Dennis M. Donnelly This digital document is an article from Trial, published by Association of Trial Lawyers of America on May 1, 2001. The length of the article is 1392 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | Introduction to Qualitative Research Methods by Steven J. Taylor, Robert Bogdan Over the two decades since the publication of the first edition of Introduction to Qualitative Research Methods, qualitative research has risen from a novel and controversial approach to the study of social issues to a widely practiced method for understanding how people view themselves and the world around them. New journals, university courses, handbooks, and encyclopedias are now devoted to... |
| © 2009 BrightSurf.com |